Kiran Gandhi

Title: Kiran Gandhi: Innovator in Plasma Kallikrein Inhibition

Introduction

Kiran Gandhi is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of plasma kallikrein inhibitors. His innovative work has led to the creation of new solid forms of these inhibitors, which have important implications for medical treatments.

Latest Patents

Kiran Gandhi holds a patent for "Solid forms of a plasma kallikrein inhibitor and salts thereof." This patent describes new solid forms of the plasma kallikrein inhibitor, specifically 1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}methyl)-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide and its salts. This innovation is crucial for enhancing the efficacy and stability of the inhibitor.

Career Highlights

Kiran Gandhi is associated with Kalvista Pharmaceuticals Limited, where he continues to advance his research and development efforts. His work at Kalvista has positioned him as a key player in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.

Collaborations

Some of Kiran's notable coworkers include David Malcolm Crowe and Edwin Aret. Their collaborative efforts contribute to the ongoing success and innovation at Kalvista Pharmaceuticals Limited.

Conclusion

Kiran Gandhi's contributions to the field of plasma kallikrein inhibition exemplify the impact of innovative thinking in pharmaceuticals. His patent and work at Kalvista Pharmaceuticals Limited highlight the importance of research and collaboration in developing effective medical treatments.